Physician profile
Robert L Treft
NPI 1851361539
$3,999.53
in general payments reported to CMS, 2019-2025
14 companies · $20.21 in 2025
The $20.21 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,004 · 2020: $595 · 2021: $1,346 · 2022: $34.74 · 2025: $20.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $1,227.00 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $915.89 | 2019 | |
| Allergan, INC. | $464.37 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $231.79 | 2019-2021 | |
| Alcon Vision LLC | $230.12 | 2019-2021 | |
| Ivantis, INC | $192.81 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $162.87 | 2019 | |
| Sun Pharmaceutical Industries INC. | $154.13 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $137.58 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $136.05 | 2019 | |
| Glaukos Corporation | $67.43 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $34.74 | 2022 | |
| Biotissue Holdings INC. | $25.35 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Treft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.